MEDISINSK SENTER FOR OVERVEKT OG FORSKNING AS

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Organization

CEO: GB
Grethe Støa Birketvedt1942
Chairman of the board: GB
Grethe Støa Birketvedt1942
Years since formation: 29 years; since Feb 20, 1995
Type: Limited company
VAT registered: No
Number of employees: 0

Ownership

Number of shares and share classes: 100; 1 share class
Total number of shareholders: 1; person

Financials

Total operating income 2023: 5,000; NOK
Annual total result 2023: 630,174; NOK
Total equity 2023: 1,223,055; NOK

Last update: Aug 29, 2024

Management

Management / administration

Name	Role	Shares
GB Grethe Støa Birketvedt 1942	Managing Director/CEO	100 % directly

Board

Name	Role	Shares
GB Grethe Støa Birketvedt 1942	Chairman	100 % directly
ET Erling Thom 1939	Alternate Member	-

Others

Name	Role	Shares
A ABACUS ØKONOMITJENESTER AS	Accountant	-

Top 10 individual shareholders

Name	Role	Shares
GB Grethe Støa Birketvedt 1942	Managing Director/CEO, Chairman	100 % directly

Last update: Apr 13, 2023

Ownership

Company shareholders

Name	Share class	Number of shares	Share
GB Grethe Støa Birketvedt 1942	Ordinary shares	100	100 %

Shares owned by the MEDISINSK SENTER FOR OVERVEKT OG FORSKNING AS

Name	Share class	Number of shares	Share
Z ZOBRIUS PHARMA ASA	Ordinary shares	140,000	0.91 %
P PROXIMAR SEAFOOD AS	NO0010893902	4,000	< 0.01 %
V VOW GREEN METALS AS	NO0011037483	1,840	< 0.01 %
A AKER HORIZONS ASA	NO0010921232	238	< 0.01 %
Y YARA INTERNATIONAL ASA	NO0010208051	55	< 0.01 %
T TELENOR ASA	NO0010063308	1,850	< 0.01 %
V VOW ASA	NO0010708068	1,030	< 0.01 %
U ULTIMOVACS ASA	NO0010851603	80	< 0.01 %
Z ZAPTEC ASA	NO0010713936	200	< 0.01 %
E EXACT THERAPEUTICS AS	NO0010852213	750	< 0.01 %

Last update: May 24, 2024

Financials

in NOK

Summary

Year	2023	2022	2021
Total operating income	5,000	0	3,758
Annual Total Result	630,174	-889,781	263,703
Total assets	1,318,826	632,908	1,482,850
Total liabilities	95,771	40,027	189
Total equity	1,223,055	592,881	1,482,662

P&L

Year	2023	2022	2021
Total operating income	5,000	0	3,758
Total operating costs	80,478	112,733	97,826
Operating result	-75,478	-112,733	-94,068
Financial income/costs	705,651	-777,048	357,772
Profit before tax	630,174	-889,781	263,703
Total tax & extraordinary income/cost	0	0	0
Annual Total Result	630,174	-889,781	263,703

Balance overview

Year	2023	2022	2021
Total fixed assets	10	10	10
Total current assets	1,318,816	632,898	1,482,840
Total assets	1,318,826	632,908	1,482,850
Short term debt	95,771	40,027	189
Long term debt	0	0	0
Total liabilities	95,771	40,027	189
Contributed capital	100,000	100,000	100,000
Retained earnings	1,123,055	492,881	1,382,662
Total equity	1,223,055	592,881	1,482,662
Total equity and liabilities	1,318,826	632,908	1,482,850

MEDISINSK SENTER FOR OVERVEKT OG FORSKNING AS966 581 050